Groupe la Francaise Lowers Stake in Boston Scientific Corporation $BSX

Groupe la Francaise decreased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 88.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,419 shares of the medical equipment provider's stock after selling 307,482 shares during the quarter. Groupe la Francaise's holdings in Boston Scientific were worth $1,679,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in BSX. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $26,000. Sfam LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $29,000. Finally, South Plains Financial Inc. acquired a new position in Boston Scientific in the 4th quarter valued at about $39,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX stock opened at $45.00 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm has a fifty day moving average price of $47.04 and a 200 day moving average price of $55.18. The company has a market cap of $65.22 billion, a P/E ratio of 18.22, a PEG ratio of 1.10 and a beta of 0.57. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific's quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares of the company's stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on BSX shares. Wall Street Zen lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 2nd. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $60.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Needham & Company LLC reduced their target price on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a report on Wednesday, July 8th. Wells Fargo & Company decreased their price target on shares of Boston Scientific from $55.00 to $50.00 and set an "equal weight" rating for the company in a research report on Thursday, July 30th. Finally, Raymond James Financial restated an "outperform" rating and issued a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and an average price target of $71.62.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing and shipping operations are recovering, which could limit the disruption and support a gradual rebound in revenue and profitability. The company also expects multiple product launches and cost savings to aid longer-term growth. Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
• Neutral Sentiment: The company has not provided a replacement forecast, leaving investors without clear visibility into the size or duration of the financial impact. Management’s ability to restore systems and normalize shipments will be key near-term catalysts. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: Boston Scientific said it is unlikely to meet its 2026 net-sales growth and earnings-per-share guidance ranges, including its previously issued third-quarter and full-year outlook. That reversal is driving the stock’s decline because it signals weaker near-term revenue, profit and cash-flow expectations. Boston Scientific Won't Meet Guidance Due to Cyberattack
• Negative Sentiment: The incident adds operational and execution risk to pressure already affecting parts of the portfolio, including WATCHMAN and electrophysiology products. Investors are now likely to focus on the timing of the recovery, the ultimate size of the earnings shortfall and whether customer orders can be fully restored. Boston Scientific's 2026 Growth Outlook Weakens

Boston Scientific Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.